Q-omics provides the consensus-scored DUSP29 profile across patient tissues and cancer cell-line models. DUSP29 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, DUSP29 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, DUSP29 RNA expression shows 8,832 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, HNSC, and THYM as cancer lineages where DUSP29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUSP29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUSP29 survival associations across molecular data types. DUSP29 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUSP29 RNA expression–survival associations across cancer types. High DUSP29 expression shows unfavorable associations in HNSC, READ, LUAD and THCA, but favorable associations in SCLC and UCEC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for DUSP29 RNA expression.
This table summarizes DUSP29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DUSP29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUSP29 shows lower tumor expression in HNSC, PAAD, STAD and COAD and higher tumor expression in KIRC. The HNSC box plot shows higher DUSP29 RNA expression in normal versus tumor tissue (log2 FC = −1.223, t-test p = .002).
This table shows molecular features associated with DUSP29 in patient tissues and cancer cell lines. In patient samples, DUSP29 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DUSP29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_NSCLC_LUAD.
